Normalization and cross-sectional validation of an extended adverse event profile (E AEP) in a large cohort of patients with epilepsy

Anti-seizure medication (ASM) is the first-line symptomatic treatment of epilepsy. Understandingly, patients ’ and their caregivers’ primary hope and expectation regarding treatment aim is seizure control. Next in line, however, is the anticipation that seizure control will not be achievable only at the cost of adverse side effects. [1] Although patients might be willing to accept side effects in the p rospect of becoming seizure free, this willingness is slight, and it is particularly low with regard to psychiatric and cognitive side effects.
Source: Seizure: European Journal of Epilepsy - Category: Neurology Authors: Source Type: research